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Radiation therapy is a highly technology driven discipline, 
and as treatments become more complex and automated, 
safe implementation and quality assurance become less 
intuitive. Moreover, the discipline seems to face a 
dichotomous situation in that on one hand there is a 
tendency towards truly individualized treatments adapted to 
patient specific characteristics, short or long term variations 
in anatomy and delivered dose, that require flexible 
interventions and optimizations. These individualized 
treatments call for dedicated QA/QC programs. On the other 
hand the automatization in delineation and treatment 
planning in combination with the need to optimize 
workflows, drive development towards template driven, 
almost “app-like” solutions. The latter, seems to facilitate 
workflows and QA/QC procedures in that a strong 
standardization reduces the need for detailed verification. In 
fact, commercial solutions are being offered as “plug-and-
play” with limited user interaction and QA/QC, almost 
ignoring the department’s responsibilities towards patient 
safety and quality. Mix the previous with rapid succession of 
upgrades and updates, and it becomes clear that the 
assessment and QA of technology (still) requires constant 
attention and vigilance. Special care should be given to the 
workflow and how the individual components are integrated 
and mutually influence each other in this constantly evolving 
and increasingly complex situation. The presentation will also 
focus on the discussion between “one shoe fits all” solutions 
versus the need for dedicated technology. Are these 
decisions driven by clinical relevance or a “me-too” 
argumentation? Finally, some comments will be given 
comparing mono-vendor and multi-vendor situations. 
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Protocols to efficiently generate small genomic sequence 
alterations in a targeted fashion are of great value to 
fundamental and clinical applications. We are particularly 
interested in developing protocols to correct the genetic 
defects underlying bone marrow failure in Fanconi anemia 
patients.  
The most promising protocols for targeted correction or 
deletion of small mutations in terms of efficiency and facility 
make use of site-specific nucleases designed to generate a 
DNA double-strand break (DSB) in the genomic DNA closely 
located to the site to be modified. The Streptococcus 
pyogenes derived RNA-guided nuclease Cas9 combines strong 
and site-specific endonuclease activity with unprecedented 
design simplicity. By exploiting the endogenous error-free 
homology-directed repair (HDR) pathway that makes use of 
sequence homology, repair of the DSB can be accompanied by 
the introduction of specific base-pair alterations. When a 
double- or single-stranded DNA template is offered, the HDR 
reaction copies subtle sequence alterations present in the 
template sequence effectuating their introduction into the 
genomic DNA. For introduction of small alterations, short 
chemically synthesized single-stranded DNA oligonucleotides 
comprising 80-120 nucleotides are highly effective. We have 
optimized the protocol for single base-pair substitution in the 
genome of mouse embryonic stem (ES) cells by 
oligonucleotide-templated HDR of a CRISPR/Cas9-generated 
break, achieving precise introduction of a planned 
modification in 50% of the recovered cells. Furthermore, we 
studied the influence of the cell’s DNA mismatch repair 
system on the efficiency of gene modification.  
Fanconi anemia (FA) is a recessive heritable disorder 
characterized by skeletal abnormalities, progressive anemia 
and cancer predisposition. The disease is caused by bi-allelic 
defects in any of 17 genes, designated FANCA, B, C, etc. 
When a matching donor is available, bone marrow failure can 
often be treated by hematopoietic stem cell transplantation. 
Also, bone marrow transplantation from a non-matching 
donor can be offered, however, this is often associated with 
severe complications. An alternative strategy to re-establish 
a functional hematopoietic system may be the functional 
correction of the FA defect in the patient’s own cells. 
Ideally, the defect is restored in the patient’s own 
hematopoietic stem cells (HSC), which can subsequently be 
used to reconstitute the entire hematopoietic system. For FA 
patients with insufficient bone marrow cellularity, the FA 
defect may first be corrected in patient-derived primary 
fibroblasts. The corrected fibroblasts subsequently need to 
be reprogrammed into HSCs, most likely requiring the 
generation of induced pluripotent stem cells (iPSCs). As a 
first step towards this approach, we demonstrated that 
CRISPR/Cas9 genome editing can effectively be exploited to 
repair a deleterious mutation in Fancf and restore the FA 
pathway in cultured mouse ES cells and fibroblasts.  
The next step is to use this protocol to correct the Fancf 
mutation in mouse-derived hematopoietic stem cells (HSC) 
and iPSCs. Gene-edited HSCs will subsequently be 
transplanted into lethally-irradiated recipient mice to 
determine their potential to drive long-term hematopoiesis. 
These preclinical studies are aimed to pave the way for the 
clinical development of CRISPR/Cas9-mediated gene 
correction protocols to restore FA gene defects and relieve 
bone marrow failure in Fanconi anemia patients. 
 
Teaching Lecture: Partial Breast Irradiation: who, when 
and how?  
 
 
SP-0003  
Partial Breast Irradiation: who, when and how? 
C. Coles
1Addenbrooke's Hospital, Oncology Centre University of 
Cambridge, Cambridge, United Kingdom 
1 
 
This lecture will explore the rationale for partial breast 
irradiation and then discuss the results from randomised 
trials to date. These will include intra-operative 
radiotherapy, brachytherapy and external beam 
radiotherapy. There is considerable heterogeneity between 
these techniques in terms of target volume, dose and 
fractionation and possible consequences from these 
differences will be considered. Appropriate patient selection 
for partial breast irradiation and treatment outside clinical 
trials will also be discussed. 
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Radiotherapy plays an important role in the treatment of 
pelvic tumors. The advances in patients’ prognosis come at 
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the expense of radiation-induced late toxicity. Progressive 
cell depletion and inflammation are the leading mechanisms 
of acute toxicity which is observed during or shortly after 
treatment. The pathogenetic pathways of late toxicity, 
developing 90 days or later after the onset of radiotherapy, 
are more complex and involve processes such as vascular 
sclerosis and fibrosis. Since many patients have become long-
term survivors, awareness and recognition of radiation-
related toxicity has gained in importance and increased 
efforts are made for its prevention and management.  
Technical innovations contribute to a reduction in 
radiotherapy-associated toxicity. The steep dose gradients of 
highly-conformal radiotherapy techniques allow for an 
accurate dose delivery with optimal sparing of the normal 
tissues. Several studies have demonstrated the dosimetrical 
benefit of intensity-modulated radiotherapy (IMRT) and 
volumetric modulated arc radiotherapy (VMAT) compared to 
conventional radiotherapy techniques. It has been shown that 
the dosimetrical benefit of IMRT translated into a clinically 
significant reduction in lower gastrointestinal toxicity 
compared with three-field conventional radiotherapy. In the 
near future MRI-linacs and proton therapy are likely to 
broaden the therapeutic window further. Prone positioning 
on a bellyboard reduces small bowel toxicity by pushing away 
the small bowel loops from the high dose region. Image-
guided radiotherapy allows for an accurate definition, 
localization and monitoring of tumor position, size and shape 
before and during treatment and may help to reduce set-up 
margins.  
Small randomized controlled trials have shown that the 
administration of several agents might have a beneficial 
effect for the prevention of acute (e.g. intrarectal 
amifostine, oral sulfasalazine and balsalazide) and/or late-
onset radiation-induced toxicity (intrarectal beclomethasone 
and oral probiotics). Once severe toxicity develops, total 
replacement of the diet with elemental formula may be 
appropriate. Probiotics influence the bacterial microflora and 
seem promising in reducing the incidence and severity of 
radiation-induced diarrhea. Currently there is insufficient 
evidence for cytoprotective and anti-inflammatory drugs in 
the management of radiation-induced toxicity. Future 
challenges lie in the prediction of treatment-related toxicity, 
which might be a promising step towards an individualized 
risk-adapted treatment. 
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As the cure rates for childhood cancers continue to improve 
with better local control and outcome, the incidence and 
management of long-term consequences are a constant 
challenge. Conservative treatments include a combination of 
chemotherapy, radiotherapy and surgery that may lead to 5 
year-survival rates > 90%. The use of brachytherapy, 
whenever feasible, is an attractive alternative when ionizing 
radiation is needed for the treatment of paediatric cancers, 
especially rhabdomyosarcomas (RMS). In genital RMS, 
brachytherapy represents an alternative to radical surgery: 
hysterectomy or colpectomy in girls and cysto-prostatectomy 
in boys. When brachytherapy is properly applied, the 
probability of late complications remains low with a high 
cure-rate. At Gustave Roussy Hospital, since decades, 
brachytherapy –when possible– has been proposed as an 
alternative to external irradiation or radical surgery. So far, 
more than 150 children have been treated with 
brachytherapy, in the context of multidisciplinary approach, 
including chemotherapy +/- conservative surgery. The most 
frequent tumour sites were vagina/uterine cervix, 
bladder/prostate and nasolabial fold, the most common 
histopathological type being RMS. In a series of 39 girls 
treated between 1971 and 2005, interstitial brachytherapy 
was used for vulval tumors, and endocavitary brachytherapy 
was used in vaginal tumours with individually tailored 
moulded vaginal applicators. Among them, 20 patients were 
treated before 1990, where the initial tumoral extension was 
included in the brachytherapy volume, while after 1990, only 
residual disease after initial chemotherapy was treated. The 
usual prescribed dose was 60-65 Gy delivered in one to three 
brachytherapy applications, taking into account the doses to 
organs at risk. With a median follow of 8.4 years, local 
recurrence was reported in 2 patients (5.1%) in the first year 
following the treatment, regional relapse in 1 patient (2.6%) 
and distant recurrences in 7 patients (17.9%). Among the 20 
patients treated before 1990, 15 presented long-term 
sequelae, (vaginal or urethral sclerosis or stenosis) with three 
requiring surgical treatment. By contrast, among the 19 
patients treated after 1990, four patients had vaginal or 
urethral stenosis, none of them requiring surgery. A recent 
long-term toxicity analysis confirmed the increase of the 
total number of G3-4 late effects in patients treated before 
1990. From 1991 to 2007, 26 boys with bladder/prostate RMS 
were treated with brachytherapy as a perioperative 
procedure. All of them underwent a conservative surgical 
procedure, with bladder-neck and urethra preservation. 
Brachytherapy was systematically performed after tumor 
resection, consisting of two loops encompassing the prostate 
and the bladder-neck area. A total dose of 60 Gy was 
delivered with low dose rate. With a median follow-up of 4 
years (10 months-14.5 years), only one patient locally 
relapsed out of the brachytherapy treated area. Among 11 
boys older than 6 years, 9 (82%) were normally continent, 
two had diurnal dribbling treated by bladder education. 
Recently, sexual and urinary functions, assessed with a 
quality of life (QoL) questionnaire, were studied in a cohort 
of 22 long-term survivors. The results showed that the great 
majority of long terms surviving males (76%) considered 
themselves as having normal QoL. Between 1971 and 2005, 16 
children with RMS of the nasolabial fold were treated with 
brachytherapy. Ten presented embryonal RMS and six 
alveolar RMS. In 12 cases, brachytherapy was combined with 
local excision. The doses ranged from 50 to 70 Gy, depending 
on chemotherapy response, and surgical margins. With a 
median follow-up of 4.4 years (1.7–33), 10 patients relapsed: 
4 local, 6 regional, and 2 metastatic failures were reported. 
In this particular context, brachytherapy provided an 
acceptable local control rate, but with a poor regional 
control. The ballistic interest of BT has been clearly 
demonstrated in paediatric RMS, with a very high dose 
gradient, sparing normal tissue and very high tumor dose. In 
our experience low dose-rate brachytherapy was used and 
recently had to move to pulsed dose-rate brachytherapy. 
Such conservative approach, minimizing late sequelae 
without detrimental effect on local control, should be 
offered whenever possible. This treatment is a clear 
demonstration of the multidisciplinary team approach, 
including surgeons, pediatricians and radiation oncologists. 
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Radiotherapy has relied on computed tomography (CT) for 
both target definition and treatment planning during the last 
decades. However, the increasing accuracy in radiation 
delivery, through highly conformal techniques such as 
intensity modulated radiotherapy (IMRT) and image guided 
